opto-dBET1

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Nameopto-dBET1
Drug Alias Nameopto-dBET1
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionBromodomain and extra terminal domain protein modulatorsProteolysis
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHarvard Medical SchoolIcahn School Of Medicine At Mount SinaiDana-Farber Cancer Institute +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe 2nd Affiliated Hospital And Yuying Children'S Hospital Of Wenzhou Medical University, Zhejiang Of ChinaIcahn School Of Medicine At Mount Sinai +[4] 
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A